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Abstract: Superficial basal cell carcinoma comprise up to 25% of all histological sub-types. 
They are more likely to occur on younger persons and females and although generally more 
common on the trunk, also occur frequently on the exposed areas of the head and neck especially 
in areas of high sun exposure. In the last decade, new treatment options such as topical 
applications that modify the immune response have been trialed for effectiveness in treating 
these lesions. Imiquimod 5% cream has been shown to stimulate the innate and cell mediated 
immune system. The short-term success of imiquimod 5% cream in randomized controlled 
trials comparing different treatment regimes and dosing as a treatment for small superficial 
basal cell carcinoma (BCC) not on the face or neck is in the range of 82% for 5 times per week 
application. A high proportion of participants with good response rates to topical treatment 
(58%–92%) experience local side effects such as itching and burning, less commonly erosion 
and ulceration, but the proportion of participants ceasing treatment has not been high. To date 
one long-term study indicates a treatment success rate of 78%–81% and that initial response is a 
predictor of long-term outcome. Recurrences tend to occur within the first year after treatment. 
Future research will compare this preparation to the gold standard treatment for superficial 
BCC – surgical excision.
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Introduction
Basal cell carcinoma (BCC) is the most common skin cancer in fair skinned populations 
and the incidence of BCC continues to rise by approximately 10% per year. BCC can 
be classified into different histological sub-types according to their growth pattern.1,2 
The different histological sub-types broadly distinguish between nodular, superficial 
and infiltrative and other less frequently occurring types according to their growth 
patterns.3 Micro-nodular and infiltrative sub-types are recognized as high risk and 
should rarely be treated other than surgically. Apart from the histological appearance, 
other well- recognized factors that can influence the prognosis and outcomes for treated 
BCC are the size and site of the tumor, how clearly the margins are defined and failure 
of previous treatment.2
The aim of this review is to examine the literature to identify the factors that can 
help a clinician decide whether or not the topical application imiquimod 5% cream is 
an appropriate treatment for a patient with the superficial sub-type of BCC (sBCC). 
The paper will outline the evidence supporting its use and the situations in which it is 
most likely to be successful, the most appropriate treatment regime and the expected 
disadvantages and side-effects of this treatment modality for this type of lesion.Clinical, Cosmetic and Investigational Dermatology 2009:2 66
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Review criteria
The information for this review was compiled by searching 
the PubMed, Cochrane, MD Consult and DARE databases 
and hard copy and electronic journals of dermatology, 
cancer and therapeutics. The search terms used included 
‘reviews’ and ‘trials’, ‘randomized controlled trials’ ‘basal 
cell carcinoma’ ‘superficial basal cell carcinoma, ‘sBCC’ and 
‘BCC’ and ‘treatment with imiquimod’ ‘cost of treatment.’ 
Electronic early-release publications were also included. Only 
articles published in English were considered. When possible, 
primary sources have been quoted. Full articles were obtained 
and references were checked for additional material when 
appropriate. References were chosen on the basis of the best 
clinical or laboratory evidence, especially if the work had been 
corroborated by published work from other centers.
Definition and epidemiology  
and of sBCC
The superficial type BCC makes up 25%–26% of all BCCs 
in sun-exposed Australians with age-standardized incidence 
rates of 337/100,000/year for males and 251/100,000/year for 
females compared with 15%–16% of the total types in Europe.4 
From reports in Europe the superficial type is more likely to 
occur on the trunk and in the younger age groups especially 
in females.5 In Australia, although still less common than the 
nodular type, compared with Europe, there are proportionately 
more sBCC, and in females the incidence is maximum in the 
40–49 years age group. The relative tumor density is highest 
on the face although the highest proportion of sBCC is on the 
trunk in males.4 Clinically, sBCC are erythematous, slightly 
scaly, well-defined patches, most commonly found on the trunk 
and the limbs. However, as mentioned in highly sun-exposed 
population are also common on the face.4 They grow slowly 
and can be confused with patches of psoriasis or eczema or 
even fungal infections Although the lesion is more likely to 
be superficial, they can be large (10 mm) identifying the 
margin when excising the lesions can be quite difficult, and 
they may be inadequately excised and so recur.6 Recurrence of 
excised BCC can occur up to 10–20 years post treatment and 
may potentially exceed 50%. However, this does not neces-
sarily apply to sBCC types.7 Understanding the etiology and 
histopathology of these lesions is important because it helps 
to explain the difficulty in clinical diagnosis and therefore the 
role of an immune response modifier in treatment.
etiology
Evidence suggests that BCC may arise from the pluripotent 
cells in the basal layer or follicles of the skin. Mutations 
in the PATCHED (PTCH) gene, a negative regulator of 
hedgehog signaling, located on chromosome 9 appear to be 
responsible for the tumor growth in basal cell nevus syndrome 
(BCNS), an autosomal condition characterized by multiple 
BCCs. Mutations in the PTCH gene have also been reported 
in sporadic cases of BCC and xeroderma pigmentosum 
associated with BCC. A recent study that focused on cases of 
sporadic BCC showed that almost half of the tumors examined 
bore PTCH gene mutations, and the percentage and type of 
these mutations did not differ significantly among patient 
groups that had regular, multiple, or early-onset BCC.8
In general, BCCs are made up of nests of cells representing 
the basal epidermal layers with peripherally palisading cells. 
The cells have hyperchromatic nuclei and scant cytoplasm. 
The nests of tumor cells are surrounded by stroma. Intercellular 
bridges are not visible on light microscopy. Mitotic figures are 
common but the whole appearance is one of uniformity rather 
than anaplasia. Ulceration is not uncommon in large tumors. In 
long-standing or aggressive lesions, extension is often diffuse 
or in the paths of cutaneous adnexae. Perineural invasion is 
seen in about 1% of cases, more frequently in aggressive forms 
of BCC. A variable inflammatory infiltrate is often present, 
usually with a majority of (CD4+) T cells. There is a prominent 
stroma arranged in bundles around the tumor masses. The 
(multifocal) superficial type is characterized by numerous 
small nests of tumor cells usually attached to the undersurface 
of the epidermis by a broad base. Approximately 10%–15% 
of all BCCs are of this type. This is the most common pattern 
seen in BCCs of the shoulder.6,8,9
Treatment options for sBCC
There are a variety of treatment options for BCC as a whole, 
including the superficial sub-type; however, little research has 
been done comparing the treatment options for this specific 
sub-type taking into account such factors as age of the patients, 
body site of the lesions, operator skills, with adequate follow-
up and assessing in addition to recurrence rates, the patient 
outcomes of cosmesis and quality of life (QOL).10
In examining the role of topical applications for the sBCC 
it may therefore be necessary to define more clearly where 
surgery is inappropriate or not first line treatment so that 
the less invasive options such as topical applications can be 
recommended.
Surgery and destructive modalities 
in the treatment of sBCC
Included in the surgical option for treatment are a number 
of different modalities including complete primary excision, Clinical, Cosmetic and Investigational Dermatology 2009:2 67
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Mohs surgery and the destructive treatments of curettage and 
cautery, and cryosurgery.1 These procedures have pros and 
cons when it comes to sBCC.
The overall treatment with the best evidence base for 
primary sBCC and other subtypes is still surgical with recur-
rence rates of 2% and good cosmetic results. This outcome 
depends significantly on the size of the lesion. For a tumor 
2 cm, the control rate at 5 years expected at 95% with a 
tumor 5 cm and deeply invading beyond subcutaneous 
tissues having a control rate from as low as 50%.2,11 The reason 
for a good outcome for surgery is the ability to examine the 
histopathology of specimens and to determine the adequacy of 
margins. Successful primary excision reduces the recurrence 
of any type of BCC including sBCC.11 In general, nodular 
and superficial sub-types, which account for the majority of 
lesions, do not have aggressive features and have a higher 
rate of complete excision and lower recurrence rates.12,13 
Nevertheless, up to 38% of tumors in one series were mixed 
sub-types of BCC, and so what appears to be a simple sBCC 
may behave like the most aggressive sub-component which 
is unrecognized clinically and may be missed even when 
biopsied.14 GPs in Australia who treat most sBCC in their 
practices report treating over half (57%) with surgery.15
Mohs surgery in general would not be undertaken for a 
sBCC unless a recurrent lesion on a high risk area. It is a highly 
specialized surgical procedure combining staged procedures 
with examination of all margins, and aims to remove all tumor, 
with tissue sparing and reconstruction if necessary. It is a pro-
cedure not available in all areas of high skin cancer incidence,14 
and it is generally reserved for high risk or recurrent lesions 
and where there is perineural or perivascular involvement.2
The strength of the evidence for use of curettage and cautery 
alone is weak and limited to evidence provided by multiple 
time series and successful results depend on careful selection 
of low risk lesions, preferably not on the face where it is less 
successful and on the skill and experience of the operator.2 It 
has been a preferred method used by dermatologists to treat 
primary nBCC and sBCC  1.5 cm although recent data on 
recurrence rates are limited.16 It has been used in conjunction 
with newer treatments such as topical applications and PDT 
especially for nodular BCC17,18 and will be discussed further 
below in association with the use of imiquimod cream.
Cryosurgery is a common form of treatment for BCC in 
dermatological practice where it is most suitable for primary, 
well-defined superficial lesions of low risk on other than 
the head and neck.11 Many large older studies demonstrate 
satisfactory cure rates. One review including studies up to and 
including 1997, suggested recurrence rates with this modality 
of from 4% to 17%.19 A more recent review revealed that there 
is a dearth of prospective, randomized controlled trials with 
a 5-year follow-up and that recurrence rates are variable.20 
Success is technique dependent and one review of multiple 
series reported a recurrence rate of 7.5% compared with other 
treatment modalities.21 This technique has been successfully 
used to treat sBCC with single freeze thaw cycles achieving 
cure rates of 96%.22 One of the disadvantages of this type of 
treatment is the perioperative pain, tenderness, blistering and 
sloughing of necrotic tissue, with possible hypopigmentation 
and scarring as the outcome and the difficulty associated with 
identifying recurrence in scar tissue.23
In the most recent Cochrane review of interventions for 
BCC10 only three randomized controlled trials (RCTs) were 
identified comparing surgical excision with an alternative 
treatment. First, surgical excision versus radiotherapy (RT)24 
which does not specifically differentiate between types of 
BCC although sBCC were included. Second, surgical excision 
versus Mohs25 which looks at high-risk BCCs only, and third, 
surgical excision versus photodynamic therapy (PDT)26 which 
includes only nodular BCC. Cryosurgery has been compared 
with radiotherapy and excision27,28 and PDT.29,30 Although the 
trial where cryosurgery was compared with PDT identifies 
sBCC (n = 39) in treatment it does not mention how these 
specifically fared following the intervention compared with 
other types. The latter trial of 5-year follow-up of treatment of 
sBCC by cryosurgery (105 lesions on 58 patients) versus PDT 
looked at (n = 114 lesions) of small size on 60 patients and 
although the outcome significantly favored PDT for patient 
tolerability and cosmesis, there was still a high recurrence 
rate of 20% for cryosurgery compared with 22% with PDT. 
These trials are outlined in Table 1. No randomized controlled 
trials (RCTS) are reported comparing cautery and curettage 
with any other treatment modality although curettage was 
used to debulk tumors in one study.28
Photodynamic therapy (PDT)
This modality uses topical photosensitizing agents aminole-
vulanic acid (ALA) and MAL, its methylated ester, which are 
applied topically to the lesion and allowed to stay on the skin 
and be absorbed for a period of time before being subjected to 
a specific light source. These agents are relatively selectively 
concentrated in the lesions and when exposed to the light source, 
usually in the wavelength of 620 to 670 nm1, this concentration 
results in photodestruction of the lesion. Other light sources 
are also used in PDT including lasers, filtered xenon arc and 
metal halide lamps, fluorescent lamps and light-emitting diodes. 
Studies have suggested there is a place for the treatment of Clinical, Cosmetic and Investigational Dermatology 2009:2 68
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sBCC with PDT,2 although they may not clear with a single 
treatment and that results are better with two cycles.31 One RCT18 
examined sBCC (n = 245 lesions on 83 patients) using topical 
ALA and 2 different light sources and there was no significant 
difference in the clinical or cosmetic outcomes at 6 months. 
As mentioned above, PDT has been compared with cryosurgery 
in an RCT, but not specifically for sBCC and not against other 
noninvasive modalities such as topical 5-fluorouracil (5FU) 
which has Federal Drug Authority approval for treatment of 
sBCC where conventional methods are impractical, or the 
immune-response modifier imiquimod.
Topical applications
A body of literature and trials are now available looking at 
topical applications in the treatment of sBCC, although it is 
not always easy to determine whether the sub-type of BCC 
has been clearly defined.4,2 In addition, a successful outcome 
for treatment needs to be explicit and it is recommended 
that 5- to 10-year local control rates or recurrence rates are 
legitimate measures although most studies do not go beyond 
5 years.11 As with any treatment modality the desired primary 
outcome is to totally eradicate the tumor and secondly to do 
so with as good a cosmetic outcome and patient acceptance 
as possible yet comparative data for different treatments 
is sparse, with most topical application studies now either 
comparing different treatment regimes or long-term follow-up 
rather than against other intervention types.2
For example, the actual clearance rate for treatment for 
sBCC with 5FU is currently not known because of a lack of 
adequate trials. The only open-label randomized trial available 
includes superficial and nodular BCC and compared six dif-
ferent treatment regimes. Overall there was an 8% treatment 
failure for sBCC when followed up by histological examina-
tion at 3 months.32 One 1-year follow-up study comparing 5FU 
with imiquimod for actinic keratoses (AK) is reported.33
Focus on imiquimod for sBCC
Mode of action
Imiquimod is a synthetic preparation that acts as an immune 
response modifier and its clinical effect comes from cytokine 
activation of the immune system and possibly also from 
induced apoptosis in BCC cells.34 It has been used now for 
some years in the treatment of genital warts as a topical 
application where it stimulates the production of cytokines 
including interferon alpha through activation of Toll-like 
receptors (TLR) -7 on antigen presenting cells.35 It promotes 
Table 1 Comparison trials of treatment where sBCC are specifically included
Intervention trial Inclusion Follow up Outcome
excision vs RT24 Included primary tumors 
sBCC (n = 36) among 
other types, face, 40 mm
Follow-up 4 years: 
histopathology, primary  
and secondary
Primary: recurrence and 
secondary cosmesis both 
favored surgery
excision vs cryosurgery28  
Note: curettage also used to 
debulk some tumors
n = 103, sBCC, nBCC head 
and neck 2 cm
Follow-up 1 year: clinical 
superficial (cryosurgery 
n = 8, excision n = 6) 
nodular cryosurgery n = 40, 
excision n = 42
Favored surgery for cosmesis, 
and no significant difference for 
clinical recurrence
Surgical excision vs curettage plus 
cryosurgery (C&C)74
n = 100, sBCC n = 4 
(all treated with excision) 
nBCC n = 96
Follow-up 5 years n = 85 Statistically non-significant 
(C&C19.6% vs Se 8.4%)
Cryosurgery vs RT75 ? histological sub-types 
n = 93
Follow-up 1 year: 
histpathology
Favored RT comparable 
cosmetic
Cryosurgery vs PDT29 sBCC n = 39, nod n = 49 Follow-up 1 year 
Histopathology (n = 83)
Significantly favored PDT for 
patient tolerability and cosmesis. 
Recurrence 25% (11 of 44) for 
ALA-PDT and 15% (6 of 39) for 
cryosurgery.
Cryosurgery vs PDT30 sBCC n = 245, thickness 
1 mm, diam 3 mm
Follow-up 5 years (n = 193) Significantly favored PDT for 
patient tolerability and cosmesis, 
but no sig diff in recurrence 
(20% cryo vs 22% PDT)
Curettage and cautery none
Abbreviations: ALA, aminolevulanic acid; RT, radiotherapy; PDT, photodynamic therapy; C&C, curettage and cryosurgery; SE, surgical excision; sBCC, superficial basal cell 
carcinoma.Clinical, Cosmetic and Investigational Dermatology 2009:2 69
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the innate immune response and the cell-mediated immune 
pathway. This immune modification has also been shown to 
produce anti-proliferative and anti-tumor activity.36,37
In examining biopsies of sBCC before and after treatment 
and undertaking gene studies and immunohistochemistry, 
it has been found that imiquimod has an anti-tumor effect 
on sBCC. This effect is mediated by the stimulation of the 
dendritic cells in the epidermis and dermis to release inter-
feron (IFN) α and other cytokines, thus activating the innate 
immune system with activity against tumor cells resulting 
in apoptosis.38,39 A recent double blind placebo-controlled 
randomized parallel group trial designed to identify the 
early immunological events caused by the application of 
imiquimod when used to treat BCC (type not indicated) 
found that the early mode of action was characterized by 
the stimulation of a large number of genes (637) which were 
highly specific to imiquimod action, 98 of which confirmed 
previous involvement of interferon α (IFN-α). With the 
remaining genes IFN γ transcription was more prevalent 
than the former. The most striking effects after several days 
of application were on cytoxic mechanisms with significant 
increases and induction of recruitment and activation of T and 
natural killer (NK) cells within the BCC. It was hypothesized 
that that it is these secondary immune effect mechanisms that 
induce destruction of target cells. It appears therefore that 
imiquimod links multiple immune pathways and of these 
IFN-α plays a consistent but not exclusive role.40
A further possible action of imiquimod was demonstrated 
when it was applied in vitro to squamous cell carcinomas 
(SCC). It appeared to neutralize the failure of the tumors 
to express vascular E-selectin. Through this it was able to 
allow the skin-homing T cells access to the tumor to promote 
its destruction. In addition, it reduced the number of tumor 
infiltrating T regulatory cells thus tipping the balance of 
T cells within the tumor towards CD8+ T cells. Furthermore, 
it induced interleukin 6 (IL-6) production from the effector 
T cells. These actions may also be relevant to sBCC.41
It appears to have minimal impact on normal skin, does 
not increase ultraviolet (UV) induced change to epidermal 
keratinocytes or DNA and the systemic absorption is minimal, 
with 0.9% of the dose excreted in urine and 0.2% excreted 
in feces, although flu-like symptoms and headache can occur 
while using the cream especially in older patients.42,43
The effect of imiquimod has also been studied by a 
new technique of confocal microscopy. This is a non-
invasive optical technique that can be used to evaluate skin 
diseases without biopsy. Unfortunately it is very expen-
sive equipment that would not be available in all centers. 
Nevertheless in a small case control study and in one case 
report the investigators were able to demonstrate the local 
immune response following therapy with imiquimod and 
demonstrated how the previously diseased skin improved 
over time. Histology of the tissue was also carried out to 
confirm findings.44,45
Uses
In 2004, imiquimod (Aldara®; 3M, St. Paul, MN) was approved 
by the United States Food and Drug Administration (FDA) 
for the topical treatment of sBCC, based on two double-
blind, vehicle-controlled clinical studies.46,47 The indications 
for use were for the topical treatment of biopsy-confirmed, 
primary superficial BCC in immunocompetent adults, with 
a maximum tumor diameter of 2.0 cm, located on the trunk 
(excluding anogenital skin), neck, or extremities (excluding 
hands and feet), only when surgical methods are medically 
less appropriate and patient follow-up can be reasonably 
assured.48
In Australia, following results of the above Phase III trials 
where clearance rates were 82%, imiquimod cream 5% is 
approved for use by the Therapeutic Goods Administration 
for biopsy-proven primary sBCC, and solar keratoses. 
Dosing for the former is application to the lesion and 5 mm 
surrounding skin 5 times per week for 6 weeks. Treatment 
breaks are allowed for severe inflammatory reactions.11,47 For 
subsidized use under the Pharmaceutical Benefits Scheme 
it is approved for the “Treatment of superficial basal cell 
carcinoma (BCC) in immunocompetent patients who cannot 
have surgical excision, cryotherapy, or curettage with 
diathermy. The lesion must be previously untreated and the 
diagnosis confirmed by biopsy, and the patient or carer must 
be able to follow the dosing regimen.”49
Approval for use in the UK is for treatment of superficial 
BCCs that measure up to 2 cm across (diameter) on the trunk, 
neck, arms and legs (including hands and feet).50
Trials: what do they tell us?
Initial trials of imiquimod 5% cream for the treatment of 
skin cancer focused on s BCC, and were drug-company 
sponsored studies in prospective open-label dose-response 
studies in multiple centers in Australia, Europe and the 
United States. The inclusion criteria for these studies 
were primary histologically confirmed sBCC lesions, not 
previously treated, of 2 cm diameter or 0.5 mm2 and in a 
position where it could be later excised. The patients were 
to have no skin conditions, and be immunocompetent. These 
first trials indicated that imiquimod could be an effective Clinical, Cosmetic and Investigational Dermatology 2009:2 70
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treatment for sBCC and that an appropriate treatment 
regime would be a maximum of a daily application, higher 
dosing causing more and intolerable side effects. The length 
of treatment was also tested in these studies with tumor 
treatment of varying times from 6 to 12 weeks, as was the 
ability to determine clinically whether the tumor had been 
cleared.51,52 The predictive value of clinical diagnosis of 
tumor non-clearance was 39% by the investigators, but 
when clinical diagnosis of positive clearance was compared 
with histology results investigators were correct in 100% of 
cases.46 The results of these trials suggested that a clearance 
rate, based on clinical and histological examination, could 
be in the range of 73% to 88% with a maximum clearance 
rate with daily applications for 6 weeks.
Of the nine RCTs reported on imiquimod use in the 
treatment of basal cell carcinoma in the most recent Cochrane 
review,10 only four relate to sBCC, with 128 patients, 
724 patients 166 patients and 35 patients respectively35,46,47,51 
with another relating to sBCC that was a randomized open 
label study with 93 patients with sBCC.54 These studies 
are outlined in Table 2. A 3-year primary outcome with 
5-year follow-up RCT comparing the use of imiquimod 
with excisional surgery for the treatment of nodular and 
sBCC is underway in the United Kingdom.54 All the studies 
have compared the treatment intervention with vehicle and 
with different doses and dosing regimes. In the most recent 
Cochrane review all except the study undertaken by Sterry 
et al were determined to be of medium quality.
In summary, for the larger trials identified, the clearance 
rates outlined in Table 2 for once-daily 5 to 7 times per 
week dosing, ranged from overall (clinical and histological 
combined) 73% to 75%,47 77%35 to 81% to 87%.46 These 
were higher where the study included twice daily dosing, 
and lower with lower frequency of dosing. It is interesting 
to note that the histological clearance rate was higher than 
the clinically observed clearance rate35,47 as reported above. 
In a pooled analysis of 5 studies testing higher and lower 
dosing regimes for BCC (not only sBCC) there was a 50% 
reduction in the risk of early treatment failure with the more 
frequent dosing regime than the less frequent.10
Side effects and disadvantages  
of treatment
The side effects from use of imiquimod are mainly local 
site reactions. In the RCTs, these tended to be complaints 
of erosion, ulceration and induration (in the more frequent 
dosing regimes) to itching, burning or pain affecting from 
58% to 92% of trial participants.35,46,47,51 Prescribed or 
patient-initiated treatment breaks due to side effects ranged 
from 3% to 19%. An association was shown between 
severity of local site reaction and clinical response rate. The 
more reaction, the better the response.55,56 Despite this, few 
patients in any of the studies discontinued because of the 
inflammatory response.35,46,47,55,56
A recent study reported a case series of 24 patients 
(6 of whom had sBCC) examining the treatment failures 
and clinical characteristics associated with failure. The 
authors in this study emphasize the need to inform patients 
as to whether their prescribed use of imiquimod meets the 
approved uses from the drug-regulatory authority and warn 
of risks associated with transferring responsibility of care for 
a cancer to the patient rather than the physician. They advise 
long-term follow-up.57 A further study reports on persisting 
hypopigmentation following treatment.58
Cost effectiveness of treatment 
options
There have been few economic evaluations of the cost-
effectiveness of various treatment options for non-melanoma 
skin cancer – even less specifically for sBCC.11 In one study 
in Spain the cost effectiveness of treatment with imiquimod 
was compared with regular excisional surgery. The findings 
may not be generalizable because they are based on the 
Spanish health care system but the principles underlying the 
assumptions about care such as when, where and by whom 
treatment is delivered provide a framework that could apply 
to other geographical regions. The findings indicated reduced 
costs per patient cured for imiquimod compared to surgical 
treatment in either a dermatological or non-dermatological 
service. Costs of primary care physicians were only involved 
in follow-up and any subsequent late treatment failure 
costs were not included.59 On the other hand, in Australia, 
General Practitioners (primary care physicians) tend to treat 
most sBCC, and with surgery,15 although there has been no 
economic evaluation of this care specifically for sBCC in 
Australia.
Other regimes and options  
for the use of imiquimod
More recent trials have focused on the different regimes but 
with only small numbers of patients, but longer follow-up. 
Five weeks of 5% imiquimod cream once daily with a 1-week 
interval was more effective but as well tolerated as the 
8-week alternate week regimen for sBCC.60 Using occlusion 
3 days per week appeared not to improve the success rate for 
sBCC (87%) over the more conventional treatment regime of Clinical, Cosmetic and Investigational Dermatology 2009:2 71
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5 times per week for 12 weeks.53 One study reports treatment 
of 96 patients with 141 lesions, 45 of which were biopsy 
proven sBCC mainly on the face neck or scalp. The patient 
group was considered to be unsuitable for or had refused 
surgery. They used the cream 3 days per week with multiple 
applications from one sachet to reduce cost. This pragmatic 
carefully designed study produced clinical cure rates of 83% 
to 87% at 6 months and 80% to 85% at 1 year despite a less 
frequent dosing regime.61
There is also a scientific rationale for combining surgical 
techniques with the use of imiquimod either to decrease the 
initial tumor size or to debulk it or to “mop-up” residual 
tumor cells following surgery on difficult body sites.62 One 
study reports improved results from this approach. The 
numbers were small (57)and included sBCC and nBCC 
where curettage without cautery was performed and followed 
one week later by imiquimod 5% cream applied 5 times per 
week for 6 weeks. At 1-year follow-up there were no clinical 
recurrences and cosmetic results were reported as excellent.63 
A further prospective follow-up study also reports treating 
patients with biopsy confirmed BCC (unknown whether 
they were superficial type) using currettage followed by 
imiquimod. A sample of lesions were biopsied at 6 weeks 
after therapy, two of which showed BCC, but on average 
follow-up at 36 months of 101 lesions the clearance rates 
were 96% with favorable cosmetic outcome.64 Imiquimod 
has also been used as adjunctive therapy where Mohs surgery 
is planned for sBCC or nBCC. A report of where Mohs was 
undertaken for three cases of large mixed-type BCC was 
ceased after the removal of aggressive tumor components 
and the remaining sBCC received adjuvant therapy with 
imiquimod cream for 6 weeks showed no recurrences after 
a follow-up period of 20 to 34 months.65
Recurrence and long-term follow-up
At this stage, in two open label phase III studies of sBCC 
treatment regimes of once daily 5 or 7 times per week 
(n = 169) application of imiquimod 5% cream , the 2-year 
follow-up has been reported. The outcome measure has been 
a clinical evaluation rather than excision, for obvious reasons. 
This approach also mimics the reality of clinical practice. 
The treatment regime in the first study was 5 times per week 
application for 6 weeks (n = 182) of whom 178 completed 
treatment. The follow-up of this study66 has subsequently 
been published and indicates the overall efficacy of the 
treatment at 5 years (with all patients included) was 78% 
clinically cleared and 81% histological clearance. One patient 
who was clear at the 12-week visit died prior to entering 
follow-up. It was noted that if recurrences occurred in this 
study they mostly occurred during the first 9 months after the 
end of treatment. The initial response was therefore predic-
tive of long-term outcome so these authors recommend and 
encourage continued monitoring of skin lesions. The second 
study demonstrated a clearance rate of 94% at 12 weeks post 
treatment and those clinically clear at 2 years were 82% with 
no difference between five times per week treatment and 
seven times per week treatment for recurrence, but the more 
frequent dosing increased side effects.56 A further small open 
study of 5-year follow-up for 55 lesions, showed of the four 
sBCC the long-term clearance rate was 100%.67
Other reports on imiquimod  
in special case sBCC
The approval by licensing authorities has focused on the use 
of this preparation for skin malignancies on small non-head 
and neck sBCC and AK. Trials are still underway for its use 
in nBCC, Bowen’s disease, and larger lesions, these topics are 
outside this review. One case report discusses success using 
imiquimod for a patient with multiple sBCC, after failure of 
treatment with 5FU68 and a second reports on the effective-
ness of imiquimod for a single large (30 cm2) sBCC with 
histological assessment at 10 months post treatment.69 There 
are also a number of reports of case series where patients 
with BCNS (Gorlins syndrome) with multiple facial and 
trunk superficial and nodular BCC have been treated with a 
high level of success using imiquimod cream.70,71 There may 
also be a role for the treatment of sBCC occurring in high 
risk renal transplant patients with one study reporting that it 
appears to be safe on skin areas up to 60 cm2.72
Conclusion
Long-term follow-up of blinded RCTs comparing imiquimod 
with other interventions are not yet available although 
these are ongoing. Only one RCT report including sBCC is 
available for 5-year follow-up and this compares cryosurgery 
with PDT. While awaiting final outcomes of these studies 
it would appear that imiquimod should not be first-line 
treatment for superficial BCC, as surgical excision is more 
effective. However, the self-treatment regimes and demon-
strated efficacy so far are attractive.73 There is reasonable 
evidence that the use of imiquimod for small (2 cm) 
superficial BCC that occur other than on the face provides 
outcomes only marginally less satisfactory than surgery. 
There would be a place for imiquimod in treating patients 
with frequent multiple primary lesions when access to surgery 
is difficult or where clinical judgment may be influenced by Clinical, Cosmetic and Investigational Dermatology 2009:2 73
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patient factors as reported in some of the studies, eg, where 
patients may have contraindications to surgery. Cosmetic 
outcome may also be relevant since sBCC occurs more 
frequently in younger patients.
Monitoring and follow-up are important if using 
imiquimod. There are a substantial proportion of lesions that 
do not respond, and this may be because they are unrecognized 
as having mixed components even if biopsy is performed and 
patients who have one BCC are at risk of more.
Side effects that are unpleasant and unsightly such as 
erosion, ulceration, burning and stinging, although commonly 
occurring in the majority of successful treatments of sBCC, 
are a two-edged sword. They generally indicate a high level 
of immune response and are correlated with clearance of 
the lesion. When patients were warned to expect these side 
effects, as in the trials, there was a minimal drop out because 
of them.
Areas for further research
More research is needed focusing on the use of imiquimod for 
sBCC on the face, those of larger size, the relationship between 
cure rates and side effects, and in the role of imiquimod as 
adjuvant therapy to or prior to surgical procedures especially 
in cosmetically sensitive areas. In addition, since imiquimod is 
a self-treatment regime, the outcomes of treatment in patients 
in rural areas with poor access to specialized care compared 
with other approaches would be valuable.
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